Table 4 Reasons for discontinuation of immunosuppressive/antiproliferative and vasoactive agents in 181 patients with systemic sclerosis
From: Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort
Inefficacy | Adverse event | Disease stabilization | Miscellaneous | |
|---|---|---|---|---|
Methotrexate (n = 49/106)* | 20 (41%) | 15 (30%) | 10 (21%) | 4 (8%) |
Cyclophospamide (n = 35/48) | 11 (31%) | 9 (26%) | 10 (29%) | 5 (14%) |
Mycophenolate (n = 18/27) | 6 (33%) | 5 (27%) | 4 (22%) | 3 (22%) |
Azathioprine (n = 13/16) | 7 (54%) | 3 (23%) | – | 3 (23%) |
Rituximab (n = 3/6) | 1 (33%) | 1 (33%) | – | 1 (33%) |
Tocilizumab (n = 3/13) | 1 (33%) | 1 (33%) | – | 1 (33%) |
ERAs (n = 17/83) | 2 (12%) | 12 (71%) | – | 3 (17%) |
Bosentan (n = 14/71) | 1 (7%) | 10 (71%) | – | 3 (21%) |
Abrisentan (n = 2/7) | 1 (50%) | 1 (50%) | – | – |
Macitentan (n = 1/5) | – | 1 (100%) | – | – |
Iloprost (n = 8/12) | 1 (13%) | 4 (50%) | – | 3 (37%) |
Sildenafil (n = 3/15) | 1 (33%) | 2 (66%) | – | – |